Background: Abnormal liver function has been reported in patients with COVID-19 infection. The aim of our study was to report on the prevalence of liver injury in our cohort, to evaluate the association of mild versus severe liver injury with mortality in COVID-19 patients and to scrutinize the temporal pattern of viral detection and liver injury. Methods: We present data from a German cohort of 147 SARS-CoV-2 infected patients. The patients were divided into 3 groups according to their liver status during treatment. The first group included patients without elevated alanine aminotransferase or bilirubin, the third group patients meeting the biochemical criteria of acute liver failure (ALF), and the second group all other patients. Results: Liver injury was detected in 75 (50.7%) and 93 (63%) patients by admission and during treatment, respectively. ALF was associated with the male sex, younger age, and higher BMI. Mortality was associated with the presence of ALF (OR = 9.423, 95% CI: 2.410–36.858) in contrast to milder liver injury (OR 1.101, 95% CI: 0.435–2.791). In 30% of patients with mild liver injury and in 50% of ALF patients, peak liver injury was observed at a time point when the virus was no longer detectable in the respiratory tract. Conclusion: Mild liver injury was not associated with worse outcome in our cohort, and the pattern of liver injury did not fit well to the theory of SARS-CoV-2 directly causing liver impairment. Instead, severe liver injury in our cohort was associated multiple-organ failure and acute vascular events.

1.
Stang
A
,
Standl
F
,
Jöckel
K-H
.
Characteristics of COVID-19 pandemic and public health consequences
.
Herz
.
2020
;
45
(
4
):
313
5
.
2.
Welfens
PJJ
.
Macroeconomic and health care aspects of the coronavirus epidemic: EU, US and global perspectives
.
Int Econ Econ Policy
.
2020
:
1
68
.
3.
Fan
Z
,
Chen
L
,
Li
J
,
Cheng
X
,
Yang
J
,
Tian
C
, et al.
Clinical features of COVID-19-related liver damage
.
Clin Gastroenterol Hepatol
.
2020 Apr 10
.
4.
Guan
WJ
,
Ni
ZY
,
Hu
Y
,
Liang
WH
,
Ou
CQ
,
He
JX
, et al.
Clinical characteristics of coronavirus disease 2019 in China
.
N Engl J Med
.
2020 Apr 30
;
382
(
18
):
1708
20
.
5.
Wang
D
,
Hu
B
,
Hu
C
,
Zhu
F
,
Liu
X
,
Zhang
J
, et al.
Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China
.
JAMA
.
2020
;
323
(
11
):
1061
9
.
6.
Meszaros
M
,
Meunier
L
,
Morquin
D
,
Klouche
K
,
Fesler
P
,
Malezieux
E
, et al.
Abnormal liver tests in patients hospitalized with coronavirus disease 2019: should we worry?
Liver Int
.
2020 Jun 3
.
7.
Xu
X-W
,
Wu
X-X
,
Jiang
X-G
,
Xu
K-J
,
Ying
L-J
,
Ma
C-L
, et al.
Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series
.
BMJ
.
2020
;
368
:
m606
.
8.
Zhang
Y
,
Zheng
L
,
Liu
L
,
Zhao
M
,
Xiao
J
,
Zhao
Q
.
Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city, China
.
Liver Int
.
2020 Apr 2
.
9.
Cai
Q
,
Huang
D
,
Yu
H
,
Zhu
Z
,
Xia
Z
,
Su
Y
, et al.
COVID-19: abnormal liver function tests
.
J Hepatol
.
Forthcoming
2020 Apr 13
.
10.
Wendon
J
,
Cordoba
J
,
Wendon
J
,
Larsen
FS
,
Cordoba
J
,
Dhawan
A
, et al.
EASL clinical practical guidelines on the management of acute (fulminant) liver failure
.
J Hepatol
.
2017
;
66
(
5
):
1047
81
.
11.
Giannini
EG
,
Testa
R
,
Savarino
V
.
Liver enzyme alteration: a guide for clinicians
.
CMAJ
.
2005
;
172
(
3
):
367
79
.
12.
Cai
Q
,
Huang
D
,
Yu
H
,
Zhu
Z
,
Xia
Z
,
Su
Y
, et al.
COVID-19: abnormal liver function tests
.
J Hepatol
.
2020
;
73
(
3
):
566
74
.
13.
Wang
Y
,
Liu
S
,
Liu
H
,
Li
W
,
Lin
F
,
Jiang
L
, et al.
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19
.
J Hepatol
.
2020 May 11
.
14.
Guy
J
,
Peters
MG
.
Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes
.
Gastroenterol Hepatol
.
2013
;
9
(
10
):
633
9
.
15.
Anastasiou
OE
,
Widera
M
,
Westhaus
S
,
Timmer
L
,
Korth
J
,
Gerken
G
, et al.
Clinical outcome and viral genome variability of hepatitis B virus-induced acute liver failure
.
Hepatology
.
2019 Mar 01
;
69
(
3
):
993
1003
.
16.
Shi
H
,
Han
X
,
Jiang
N
,
Cao
Y
,
Alwalid
O
,
Gu
J
, et al.
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
.
Lancet Infect Dis
.
2020 Apr 01
;
20
(
4
):
425
34
.
17.
Bangash
MN
,
Patel
J
,
Parekh
D
.
COVID-19 and the liver: little cause for concern
.
Lancet Gastroenterology Hepatology
.
2020
;
5
(
6
):
529
30
.
18.
Pawlotsky
J-M
.
COVID-19 and the liver-related deaths to come
.
Nat Rev Gastroenterology Hepatol
.
2020 Jun 11
:
1
3
.
19.
Ji
D
,
Zhang
D
,
Yang
T
,
Mu
J
,
Zhao
P
,
Xu
J
, et al.
Effect of COVID-19 on patients with compensated chronic liver diseases
.
Hepatol Int
.
2020 Jul 30
:
1
10
.
20.
Singh
S
,
Khan
A
.
Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study
.
Gastroenterology
.
2020 Aug
;
159
(
2
):
768
71.e3
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.